藥物交互作用
Abrocitinib + Ticagrelor
嚴重程度: 嚴重
Abrocitinib and Ticagrelor: major interaction.
最後更新
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
摘要
Abrocitinib reduces platelet counts, mainly in the early weeks of treatment, and its labeling advises against antiplatelet drugs other than low-dose aspirin during the first 3 months. Adding ticagrelor, a potent P2Y12 inhibitor, to thrombocytopenia increases the risk of significant bleeding.
用白話說明這項交互作用的意義
Abrocitinib and Ticagrelor can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Abrocitinib belongs to Miscellaneous; Ticagrelor belongs to Cardiovascular.
為什麼會發生
Additive bleeding risk from ticagrelor platelet inhibition combined with abrocitinib-associated reduction in platelet count.
處置方式
Avoid starting abrocitinib in patients who need ticagrelor during the first 3 months, or choose an alternative therapy. If unavoidable, monitor platelet counts and bleeding signs closely.
可向藥師詢問的問題
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Ticagrelor 的其他交互作用
Abrocitinib 的其他交互作用
常見問題
Can I take Abrocitinib with Ticagrelor?
MediHelp rates the interaction as major. Abrocitinib and Ticagrelor can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Abrocitinib reduces platelet counts, mainly in the early weeks of treatment, and its labeling advises against antiplatelet drugs other than low-dose aspirin during the first 3 months. Adding ticagrelor, a potent P2Y12 inhibitor, to thrombocytopenia increases the risk of significant bleeding.
How serious is the interaction between Abrocitinib and Ticagrelor?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid starting abrocitinib in patients who need ticagrelor during the first 3 months, or choose an alternative therapy. If unavoidable, monitor platelet counts and bleeding signs closely.
What other medicines interact with Ticagrelor?
MediHelp also lists interactions of Ticagrelor with, for example, Itraconazole, Ketoconazole, Levoketoconazole. The full list is on the Ticagrelor page.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
